Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01968213 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
A Phase 3 study, sponsored by pharmaand.
- Completed
- Registry status
- Phase 3
- Development phase
- 564
- Enrollment target
NCT01968213 is a Phase 3 study that has completed, run by pharmaand. The registered enrollment target is 564 participants.
The verdict
NCT01968213, a Phase 3 study, has completed, sponsored by pharmaand.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 564 participants
- Enrollment target
Study Summary
Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus placebo. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
Interventions
- DRUG Placebo
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2014-04-07 |
| Est. Completion | 2022-07-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01968213
The ClinicalTrials.gov registry entry for NCT01968213 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 564 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01968213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01968213 about?
NCT01968213 is a clinical study titled "Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)". Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus placebo. Response to treatment will be analyzed based on homologous re...
What is the current status of trial NCT01968213?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 564 participants. The study started on 2014-04-07. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT01968213?
The interventions under investigation include: Placebo (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT01968213?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.